117037-25-9

Basic information

• Product Name: Carbamic acid, [(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-, 1,1-dimethylethyl ester
• CAS NO: 117037-25-9
• Molecular Formula: C14H21NO3
• Molecular Weight: 251.326
• Mol File: 117037-25-9.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Carbamic acid, [(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Carbamic acid, [(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-, 1,1-dimethylethyl ester(117037-25-9)
• EPA Substance Registry System: Carbamic acid, [(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]-, 1,1-dimethylethyl ester(117037-25-9)

Safety Data

• Hazardous Substances Data: 117037-25-9(Hazardous Substances Data)

Upstream product

• 138371-45-6 2-N-(tert-butoxycarbonyl)amino-1-phenyl-1-propanone 
• 16735-19-6 2-amino-1-phenylpropan-1-one hydrochloride 
• 19437-20-8 2-(1-oxo-1-phenylpropan-2-yl) isoindoline-1,3-dione 
• 2114-00-3 2-bromo-1-phenyl-1-propanone 
• 93-55-0 1-phenyl-propan-1-one 
• 24424-99-5 di-tert-butyl dicarbonate 
• 492-39-7 (1S,2S)-2-amino-1-phenylpropanol 
• 37577-28-9 (1S,2R)-(+)-norphedrine 
• 108832-95-7 tert-butyl N-(1-oxo-1-phenylpropan-2-(2R)-yl)carbamate 
• 117037-12-4 (4R,5S)-4-Methyl-2-oxo-5-phenyl-oxazolidine-3-carboxylic acid tert-butyl ester 

Downstream Products

• 108832-95-7 tert-butyl N-(1-oxo-1-phenylpropan-2-(2R)-yl)carbamate 
• 125133-96-2 (4R,5R)-4-methyl-5-phenyl-1,3-oxazolidin-2-one 
• 37577-07-4 Norpseudoephedrine 
• 125073-73-6 (1R,2R)-1-Phenyl-2-{[1-phenyl-meth-(E)-ylidene]-amino}-propan-1-ol 

Relevant articles and documents

Asymmetric Transfer Hydrogenation: Dynamic Kinetic Resolution of α-Amino Ketones

A series of α-amino ketones were reduced using asymmetric transfer hydrogenation (ATH) through a dynamic kinetic resolution (DKR). The protecting group was matched to the reducing agent, and following optimization, a series of substrates were investigated, giving products in high diastereoselectivity, over 99% ee in several cases and full conversion. The methodology was applied to the enantioselective synthesis of an MDM2-p53 inhibitor precursor.

CONJUGATE OF CELL-BINDING RECEPTOR WITH CYTOTOXIC AGENT

PROBLEM TO BE SOLVED: To provide a conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule for targeted treatment. SOLUTION: According to the present invention, there is provided a conjugate having a structure of formula (I) and a pharmaceutical acceptable salt and a solvate thereof. The conjugate is used for treating cancer, autoimmune disease, and infectious disease. (T is a targeting or binding ligand; L is a releasable linker; a broken line is a linkage bond that L connects to a molecule inside the bracket independently; n is an integer of 1 to 20; m is an integer of 1 to 10; and a structure in parentheses is a potent antimitotic agent/drug.) SELECTED DRAWING: None COPYRIGHT: (C)2017,JPOandINPIT

Conjugates of Cell Binding Molecules with Cytotoxic Agents

A conjugate of a potent cytotoxic agent with a cell-surface receptor binding molecule having a Formula (I), wherein T, L, m, n, R1, R2, R3, R4, R5, R6, R7, R8, R9